Sygnature Discovery showcases its Bioscience expertise at ELRIG Drug Discovery 2017

3rd October 2017 – Liverpool, UK – Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, is showcasing the expertise of its BioScience department at ELRIG Drug Discovery 2017 In Liverpool from 3rd – 4th October 2017.

Drug Discovery 2017 is ELRIG’s flagship event. Now in its 11th year, the conference brings together the leading lights in drug discovery research across pharma, biotech, academia and the vendor community.  Below is a summary of the Sygnature activities at ELRIG Drug Discovery 2017:


Tuesday 3rd October 2017

ESSEN Workshop Presentation:

Dr Bryan Miller

“Use of live cell imaging assays for immuno-oncology in integrated drug discovery programmes”

09:35 – 9:55 – ROOM 11A

Snapshot Presentation:

Dr Marie Fisher

“Adoption of High-Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes”

14.50 – 14.55

“Advances in Imaging” Session

Room – Hall 1B


  • Dr Bryan Miller (Poster #20): “Live cell and high-content imaging approaches to identify apoptosis inducers in cell models of triple negative breast cancer”
  • Ms Juliet Morgan (poster # 53): “Complementary biophysical approaches to assess fragment binding to the epigenetic target bromodomain-containing protein 3 (BRD3)
  • Dr Marie Fisher (poster #43): “Predicting drug-induced phospholipidosis using high resolution imaging in 2D and 3D cultures”
  • Dr Meera Raja (poster #1): “A phenotypic screen to identify novel neuroprotective agents”


Wednesday 4th October Time: 11.50

Poster spotlight presentation:

Dr Meera Raja

Track: Target ID & Validation

Room: Hall 1C

Copyright © 2018 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.